#Sweden #Stockholm #HbA1c #Capitainer #microsampling

Capitainer Reaches Regulatory Milestone in HbA1c Clinical Study

Capitainer, a Swedish company specializing in innovative volumetric microsampling solutions, has marked a significant achievement in its U.S. regulatory endeavors. On October 27, 2026, the company announced the successful collection of its first clinical sample as part of a crucial study focused on HbA1c, a vital indicator of long-term blood glucose levels. This initiative is aimed at supporting the company’s plan to submit a 510(k) application to the FDA.

Study Overview

The ongoing study is designed to engage at least 120 participants and will explore two methodologies: self-sampling and assisted capillary blood collection using Capitainer®B50 technology. A key aspect of this research is to compare the HbA1c results obtained through these microsampling techniques against those obtained from traditional venous blood samples, which have been the gold standard in blood testing for years.

Collaboration with Diagnostic Partners

For analyzing the collected samples, Capitainer is collaborating with Three Rivers Diagnostics and Aegis Sciences Corporation. These esteemed laboratories will utilize Roche's advanced laboratory instrumentation, ensuring high-quality results that will be integral to evaluating the efficacy of Capitainer's microsampling approach. The data-gathering phase of this study is projected to conclude in November 2026.

Significance of the Milestone

CEO Christopher Aulin expressed the importance of this milestone, emphasizing that it is a vital step in Capitainer's journey within the U.S. market. Aulin commented, "We see significant opportunities for microsampling technology to support more accessible blood testing and help healthcare providers address gaps in care. This study represents an important part of our long-term strategy to expand the clinical applications of our technology."

Future of Microsampling

The progress made by Capitainer reflects a growing trend in the biomedical field, where more accessible and less invasive blood testing methods are in demand. The adoption of volumetric microsampling could lead to enhanced patient compliance and comfort, ultimately facilitating better healthcare outcomes. By enabling easy self-sampling, this technology has the potential to revolutionize how blood tests are conducted, especially for routine monitoring of chronic conditions like diabetes.

Conclusion

As Capitainer advances through the stages of clinical evaluation and regulatory approval, the industry watches closely. The outcome of this study could pave the way for significant growth opportunities in the healthcare sector. With the rising need for innovative and patient-friendly testing solutions, Capitainer’s efforts in microsampling technology are indeed timely and essential. As the data collection wraps up soon, the insights gained will surely contribute to refining blood testing methodologies for better accessibility and effectiveness. For further inquiries, contact Christopher Aulin at +46 (0)708 977577 or via email at [email protected]

Capitainer’s journey exemplifies the intersection of technology and healthcare, showcasing how innovative approaches can help bridge the gaps in patient care.